Cargando…
Vacuum-Assisted Breast Biopsy System: No Innovation Without Evaluation
Background Vacuum-assisted breast biopsy (VABB) has recently been gaining more popularity as a modality to reach the final diagnosis, especially in indeterminate breast lesions, resulting in a decreased number of surgical interventions and unnecessary follow-ups. Objective While our primary aim was...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876960/ https://www.ncbi.nlm.nih.gov/pubmed/33585135 http://dx.doi.org/10.7759/cureus.12649 |
_version_ | 1783650068605173760 |
---|---|
author | Monib, Sherif Mukerji, Soumitra Narula, Sonia |
author_facet | Monib, Sherif Mukerji, Soumitra Narula, Sonia |
author_sort | Monib, Sherif |
collection | PubMed |
description | Background Vacuum-assisted breast biopsy (VABB) has recently been gaining more popularity as a modality to reach the final diagnosis, especially in indeterminate breast lesions, resulting in a decreased number of surgical interventions and unnecessary follow-ups. Objective While our primary aim was to look into the outcomes of the VABB technique, our secondary aim was to assess the impact of the method on changes in patients’ management. Patients and methods This study was a retrospective database analysis of vacuum-assisted biopsies (VABs) carried out at our breast unit during the period between January 2011 and January 2018. All our cases were image-guided; the caliber of vacuum-assisted needles used was 8 gauge (G) and 11 G. Patient demographics, lesion characteristics, and outcomes were retrieved from patients’ notes and the hospital database. Results A total of 122 female patients were included in the analysis, out of whom 41.8% (51 patients) were screen-detected, and 58.1% (71 patients) were symptomatic presentations. The mean lesion size on imaging was 14.8 mm (SD: 12.6); 50% (61 patients) had stereotactic vacuum-assisted breast biopsy (SVAB), and 50% (61 patients) had ultrasound-guided vacuum-assisted breast biopsy (US-VAB). Post-procedure histology was upgraded in 19.6% (24 patients), downgraded in 18.8% (23 patients), and remained unchanged in 61.4% (75 patients). Conclusion VABB is a safe and efficient procedure for the diagnosis and management of indeterminate and suspicious breast lesions. It provides an adequate amount of tissue, which can help in upgrading or downgrading histopathologically diagnosed patients, thereby decreasing the need for surgery. |
format | Online Article Text |
id | pubmed-7876960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-78769602021-02-12 Vacuum-Assisted Breast Biopsy System: No Innovation Without Evaluation Monib, Sherif Mukerji, Soumitra Narula, Sonia Cureus Radiology Background Vacuum-assisted breast biopsy (VABB) has recently been gaining more popularity as a modality to reach the final diagnosis, especially in indeterminate breast lesions, resulting in a decreased number of surgical interventions and unnecessary follow-ups. Objective While our primary aim was to look into the outcomes of the VABB technique, our secondary aim was to assess the impact of the method on changes in patients’ management. Patients and methods This study was a retrospective database analysis of vacuum-assisted biopsies (VABs) carried out at our breast unit during the period between January 2011 and January 2018. All our cases were image-guided; the caliber of vacuum-assisted needles used was 8 gauge (G) and 11 G. Patient demographics, lesion characteristics, and outcomes were retrieved from patients’ notes and the hospital database. Results A total of 122 female patients were included in the analysis, out of whom 41.8% (51 patients) were screen-detected, and 58.1% (71 patients) were symptomatic presentations. The mean lesion size on imaging was 14.8 mm (SD: 12.6); 50% (61 patients) had stereotactic vacuum-assisted breast biopsy (SVAB), and 50% (61 patients) had ultrasound-guided vacuum-assisted breast biopsy (US-VAB). Post-procedure histology was upgraded in 19.6% (24 patients), downgraded in 18.8% (23 patients), and remained unchanged in 61.4% (75 patients). Conclusion VABB is a safe and efficient procedure for the diagnosis and management of indeterminate and suspicious breast lesions. It provides an adequate amount of tissue, which can help in upgrading or downgrading histopathologically diagnosed patients, thereby decreasing the need for surgery. Cureus 2021-01-12 /pmc/articles/PMC7876960/ /pubmed/33585135 http://dx.doi.org/10.7759/cureus.12649 Text en Copyright © 2021, Monib et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Radiology Monib, Sherif Mukerji, Soumitra Narula, Sonia Vacuum-Assisted Breast Biopsy System: No Innovation Without Evaluation |
title | Vacuum-Assisted Breast Biopsy System: No Innovation Without Evaluation |
title_full | Vacuum-Assisted Breast Biopsy System: No Innovation Without Evaluation |
title_fullStr | Vacuum-Assisted Breast Biopsy System: No Innovation Without Evaluation |
title_full_unstemmed | Vacuum-Assisted Breast Biopsy System: No Innovation Without Evaluation |
title_short | Vacuum-Assisted Breast Biopsy System: No Innovation Without Evaluation |
title_sort | vacuum-assisted breast biopsy system: no innovation without evaluation |
topic | Radiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876960/ https://www.ncbi.nlm.nih.gov/pubmed/33585135 http://dx.doi.org/10.7759/cureus.12649 |
work_keys_str_mv | AT monibsherif vacuumassistedbreastbiopsysystemnoinnovationwithoutevaluation AT mukerjisoumitra vacuumassistedbreastbiopsysystemnoinnovationwithoutevaluation AT narulasonia vacuumassistedbreastbiopsysystemnoinnovationwithoutevaluation |